BOCA RATON, Fla., Feb. 10 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals announced today that Thomas H. McLain, chairman, chief executive officer and president, and Henrik Rasmussen, M.D., Ph.D., senior vice president, clinical, medical and regulatory affairs, will be presenting at the BIO CEO and Investor Conference 2006 on Tuesday, February 14, 2006, at 10:30 am ET at the Waldorf Astoria Hotel, Louis XVI Center/West, 301 Park Avenue, New York, New York. Mr. McLain will present a company overview, and Dr. Rasmussen will speak about NicVAX(TM) (Nicotine Conjugate Vaccine), the company's pipeline product for nicotine cessation.
The presentation will be webcast live at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NABI&item_id=1165953
The webcast will be available through March 14, 2006.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)]. Nabi Biopharmaceuticals is focused on developing products which address unmet medical needs and offer commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis, kidney disease (nephrology) and nicotine addiction. Click here for a complete list of our pipeline products. The company traces its history to 1967 and is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website: http://www.nabi.com .
Audio: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NABI&item_id=1165953Nabi BiopharmaceuticalsCONTACT: Tom Rathjen, Vice President, Investor Relations, NabiBiopharmaceuticals, +1-561-989-5800
Web site: http://www.nabi.com/
